FAPI Development2021-05-21T17:56:07+00:00

FAPI DEVELOPMENT

FAPI

SOFIE licensed a family of theranostic compounds that target the tumor stroma from the University of Heidelberg, the team that invented PSMA-617 (Novartis). The FAPI compounds inhibit the fibroblast activation protein, which is an important cancer target. Over 500 patients have been imaged to date with the diagnostic compound and initial therapeutic studies are underway. FAPI received the Product/Image/Publication of the Year Award at the Society for Nuclear Medicine and Molecular Imaging.

“FAPI is opening new doors in nuclear medicine, not only in imaging but also in theranostics.”

Dr. Frederick Giesel, M.D, M.B.A.
Universität Heidelberg · Nuclear Medicine

PUBLICATIONS

[ 18 F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions

Bing Hao 1, Xiurong Wu 2, Yizhen Pang 1, Long Sun 1, Hua Wu 1, Weipeng Huang # 3, Haojun Chen # 4 Article available for purchase or with subscription. Affiliations: Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China. Department of [...]

February 2nd, 2021|Publications|

Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer

Artineh Hayrapetian 1, Mark D Girgis, Jane Yanagawa, Samuel W French, Heinrich R Schelbert 1, Martin S Auerbach 1, Johannes Czernin, Jeremie Calais Abstract: A 71-year-old man underwent 18F-FDG and 68Ga-FAPI-46 PET/CT for initial staging prior to surgery of a squamous cell carcinoma of the lower esophagus under the prospective study NCT04147494. Both scans showed [...]

February 1st, 2021|Publications|

Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18 F-Labeled FAP Inhibitor

Johannes Toms 1, Jürgen Kogler 1, Simone Maschauer 1, Christoph Daniel 2, Christian Schmidkonz 3, Torsten Kuwert 3, Olaf Prante 4 3 Fibroblast activation protein (FAP) has emerged as an interesting molecular target used in the imaging and therapy of various types of cancers. 68Ga-labeled chelator-linked FAP inhibitors (FAPIs) have been successfully applied to PET imaging of various tumor [...]

December 6th, 2020|Publications|

INTERESTED IN FAPI?

Guided by our Scientific Advisory Board, sanctioned peer-reviewed publications, and our own FAPI development plan, we remain committed to the process of making FAPI precursor material and radiolabeled compounds readily available.

HOSPITALS

Are you a hospital or clinic interested in participating in our clinical trial? Following the filing of its IND, we will be launching a FAPI-based clinical trial. We expect to collaborate to achieve the required designed endpoints.

RESEARCHERS

Are you an academic researcher interested in evaluating the FAPI compounds within the preclinical and clinical space for both mainstream and unique applications? Our partners at ABX will have you up and running quickly.

PHARMACEUTICAL COMPANIES

Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs. Contact us today.

COMMERCIAL PARTNERS

Trasis

SOFIE has selected an automated radiosynthesizer for standardized production of its Ga-68 FAPI and F-18 FAPI. This will facilitate production at SOFIE’s facilities for supply to its clinical trial sites.

Covance

US-based FAPI-46 and FAPI-74 Tox studies have been completed by Covance at its Indianapolis facility.

abx

ABX is SOFIE’s partner of choice for our FAPI precursor production. ABX has successfully completed the manufacture and shipment of the first stocks of FAPI precursor material, enabling our distribution of precursor and reference standards under MTAs to multiple approved users in the US and EU.

FAPI is not currently approved for general clinical use and should therefore be utilized in accordance with established regulatory guidelines in each jurisdiction.

SCIENTIFIC ADVISORY BOARD

Uwe Haberkorn, MD, PhD

Uwe Haberkorn, MD, PhD

  • Inventor of the FAPI theranostic family
  • Chair of the Department of Nuclear Medicine at the University of Heidelberg
  • Head of the Clinical Cooperation Unit of Nuclear Medicine at the DKFZ
Stefano Fanti, MD

Stefano Fanti, MD

  • Chairman of FAPI Scientific Advisory Board
  • Head of Nuclear Medicine, University of Bologna
Frederick Giesel MD, MBA

 Frederick Giesel, MD, MBA

  • Vice Chair of Nuclear Medicine, Department of Nuclear Medicine, University Hospital Heidelberg
  • Full Professor at Osaka University, Osaka Japan and expert in the field oncological theranostics
Clemens Kratochwil, MD

 Clemens Kratochwil, MD

  • Attending and Director, Therapy Unit, Department of Nuclear Medicine at the University of Heidelberg
Jens Siveke, MD

 Jens Siveke, MD

  • Head of the Division of Solid Tumor Translational Oncology (DKFZ/DKTK partner site Essen)
  • Full Professor in the Department of Medical Oncology at the West German Cancer Center, University Hospital Essen
Johannes Czernin, MD

Johannes Czernin, MD

  • Nuclear Medicine and Internal Medicine
  • Chief, Ahmanson Translational Imaging Division at UCLA
Ken Herrmann, MD, MBA

Ken Herrmann, MD, MBA

  • Chair of Nuclear Medicine at the University of Duisburg-Essen

CONTACT US

Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.

Go to Top